Latest filing published 07 Jan 2025 for Arrowhead Pharmaceuticals, INC..
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -62.9%Entry US$10.50 · Close at T+365 US$3.90
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Kenneth Allen Myszkowski: trading record in brief
Kenneth Allen Myszkowski is a declared insider of Arrowhead Pharmaceuticals, Inc. (finance chief), with filings sourced from SEC (Form 4). Between 27 August 2010 and 7 January 2025, the trades on record add up to 93 filings.
The open-market side counts 1 purchase for €11k alongside 50 sales for €21.4M. Sales outweigh purchases by €21.4M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 16 share grants and 26 option exercises. Since January 2025: no purchases and 4 sales on the market.
The record was last updated on 7 January 2025 with a share grant in Arrowhead Pharmaceuticals, Inc. The most recent open-market purchase was published on 30 August 2010, 5,914 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Kenneth Allen Myszkowski
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 100,000 shares0Common StockSEC:0001628280-25-000805:0
- 17,765 shares@ US$19.687.3% of flowCommon StockSEC:0001628280-25-000805:1
- 9,402 shares@ US$20.103.9% of flowCommon StockSEC:0001628280-25-000805:2
- 8,000 shares@ US$19.703.3% of flowCommon StockSEC:0001628280-25-000805:3
- 10,000 shares@ US$19.694.1% of flowCommon StockSEC:0001628280-25-000805:4
- 40,000 shares@ US$35.1927.8% of flowCommon StockSEC:0001628280-24-010062:0
- 1,400 shares@ US$34.040.2% of flowCommon StockSEC:0001628280-24-000866:1
- 5,800 shares@ US$34.970.8% of flowCommon StockSEC:0001628280-24-000866:2
- 8,904 shares@ US$35.651.3% of flowCommon StockSEC:0001628280-24-000866:3
- 75,000 shares0Common StockSEC:0001628280-24-000866:0
- 15,000 shares@ US$36.2010.6% of flowCommon StockSEC:0001628280-23-023950:0
- 60,000 shares0Common StockSEC:0001209191-23-002116:0
- 30,625 shares@ US$40.0024.7% of flowCommon StockSEC:0001209191-22-063020:0
- 16,528 shares@ US$62.004.0% of flowCommon StockSEC:0001209191-22-002290:1
- 3,778 shares@ US$63.170.9% of flowCommon StockSEC:0001209191-22-002290:2
- 3,786 shares@ US$63.950.9% of flowCommon StockSEC:0001209191-22-002290:3
- 15,908 shares@ US$60.5018.3% of flowCommon StockSEC:0001209191-22-002290:0
- 60,000 shares0Common StockSEC:0001209191-22-001299:0
- 11,597 shares@ US$81.023.7% of flowCommon StockSEC:0001209191-21-003295:0
- 1,441 shares@ US$81.000.5% of flowCommon StockSEC:0001209191-21-003295:1
- 1,100 shares@ US$70.750.3% of flowCommon StockSEC:0001209191-21-002577:0
- 4,359 shares@ US$71.771.2% of flowCommon StockSEC:0001209191-21-002577:1
- 25,166 shares@ US$72.637.1% of flowCommon StockSEC:0001209191-21-002577:2
- 60,000 shares0Common StockSEC:0001209191-21-001555:0
- 43,505 shares@ US$14.544.2% of flowCommon StockSEC:0001209191-20-058075:0
25 of 89 declarations
